CA2724483C - Psd-95 inhibitor for the treatment of epilepsy - Google Patents

Psd-95 inhibitor for the treatment of epilepsy Download PDF

Info

Publication number
CA2724483C
CA2724483C CA2724483A CA2724483A CA2724483C CA 2724483 C CA2724483 C CA 2724483C CA 2724483 A CA2724483 A CA 2724483A CA 2724483 A CA2724483 A CA 2724483A CA 2724483 C CA2724483 C CA 2724483C
Authority
CA
Canada
Prior art keywords
epilepsy
peptide
seq
pdz
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2724483A
Other languages
English (en)
French (fr)
Other versions
CA2724483A1 (en
Inventor
James Gurd
Crystal Dykstra
Michael Tymianski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NoNO Inc
Original Assignee
NoNO Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NoNO Inc filed Critical NoNO Inc
Publication of CA2724483A1 publication Critical patent/CA2724483A1/en
Application granted granted Critical
Publication of CA2724483C publication Critical patent/CA2724483C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2724483A 2008-05-16 2009-05-13 Psd-95 inhibitor for the treatment of epilepsy Active CA2724483C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5410908P 2008-05-16 2008-05-16
US61/054,109 2008-05-16
PCT/US2009/043831 WO2009140416A2 (en) 2008-05-16 2009-05-13 Treatment for epilepsy

Publications (2)

Publication Number Publication Date
CA2724483A1 CA2724483A1 (en) 2009-11-19
CA2724483C true CA2724483C (en) 2018-01-02

Family

ID=41319319

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2724483A Active CA2724483C (en) 2008-05-16 2009-05-13 Psd-95 inhibitor for the treatment of epilepsy

Country Status (9)

Country Link
US (1) US9161965B2 (https=)
EP (1) EP2307035B1 (https=)
JP (2) JP6005357B2 (https=)
CN (1) CN102088990A (https=)
AU (1) AU2009246316B2 (https=)
CA (1) CA2724483C (https=)
DK (1) DK2307035T3 (https=)
ES (1) ES2446306T3 (https=)
WO (1) WO2009140416A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
EP2121088B1 (en) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
DK2307035T3 (da) * 2008-05-16 2014-01-20 Nono Inc Anvendelse af en PSD-95 inhibitor ved behandlingen af epilepsi
CA2739416C (en) 2008-09-03 2017-10-31 Arbor Vita Corporation Agents and methods for treatment of pain
US20140323924A1 (en) * 2013-04-26 2014-10-30 David J. Mishelevich Targeted optogenetic neuromodulation for treatment of clinical conditions
WO2014121146A1 (en) 2013-01-31 2014-08-07 The Regents Of The University Of California System and method for modeling brain dynamics in normal and diseased states
CN113546174A (zh) 2015-02-25 2021-10-26 加利福尼亚大学董事会 用于治疗病症的5ht激动剂
EP3383429B1 (en) 2015-11-30 2020-10-14 INSERM - Institut National de la Santé et de la Recherche Médicale Nmdar antagonists for the treatment of tumor angiogenesis
KR102253900B1 (ko) * 2016-04-27 2021-05-18 바이오셀즈(베이징) 바이오테크 코., 엘티디. 흥분성 신경독성 관련 손상 치료용 펩타이드
EP3450446A1 (en) * 2016-04-27 2019-03-06 Biocells (Beijing) Biotech Co., Ltd. Treatment method for excitatory neurotoxicity-related injury
US11241383B2 (en) 2016-12-09 2022-02-08 Alexza Pharmaceuticals, Inc. Method of treating epilepsy
KR102403089B1 (ko) 2017-07-05 2022-06-02 바이오셀즈(베이징) 바이오테크 코., 엘티디. 폴리펩타이드의 약학적으로 허용 가능한 염 및 이의 용도
KR102545825B1 (ko) 2017-09-30 2023-06-22 바이오셀즈(베이징) 바이오테크 코., 엘티디. 흥분성 신경 독성 관련 손상 치료를 위한 펩타이드 조성물
CA3085576A1 (en) 2017-12-13 2019-06-20 The Research Foundation For The State University Of New York Peptides and other agents for treating pain and increasing pain sensitivity
EP3746138B1 (en) 2018-02-02 2025-12-10 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
US11911419B2 (en) * 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
CA3153099A1 (en) * 2019-09-17 2021-03-25 Zogenix International Limited Methods of treating epileptic patients with fenfluramine
CN110627877A (zh) * 2019-09-25 2019-12-31 成都奥达生物科技有限公司 一种psd-95抑制剂
CN111285923B (zh) * 2020-03-05 2023-02-03 成都奥达生物科技有限公司 一种psd-95抑制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148711A1 (en) * 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US20050019841A1 (en) * 1999-05-14 2005-01-27 Arbor Vita Corporation Modulation of signaling pathways
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
US20090075377A1 (en) * 2001-08-03 2009-03-19 Arbor Vita Corporation Molecular interactions in cells
US20050282743A1 (en) * 2001-08-03 2005-12-22 Arbor Vita Corporation Molecular interactions in cells
EP1709084A4 (en) * 2003-12-23 2008-05-28 Nono Inc POLYPEPTIDES FOR MODULATING BINDING OF TRP-CHANNEL PROTEINS AND TRP-ASSOCIATED PROTEINS
WO2005097090A2 (en) * 2004-04-05 2005-10-20 Icos Corporation AGENTS THAT DISRUPT PSD95 - nNOS INTERACTION, COMPOSITIONS CONTAINING THE SAME, AND THERAPEUTIC USES THEREOF
CA2613012A1 (en) * 2005-06-23 2007-01-04 Arbor Vita Corporation Methods and compositions for modulating cox
US20070021501A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods of treating epileptogenesis
US8633160B2 (en) * 2005-12-30 2014-01-21 Nono Inc. Small molecule inhibitors of PDZ interactions
KR101384572B1 (ko) * 2005-12-30 2014-04-24 아버 비타 코포레이션 Ｐｄｚ 상호작용의 소형 분자 억제제
EP1884521A1 (en) * 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
ES2446292T3 (es) * 2007-03-02 2014-03-07 Nono Inc. Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N
US8008253B2 (en) * 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
DK2307035T3 (da) * 2008-05-16 2014-01-20 Nono Inc Anvendelse af en PSD-95 inhibitor ved behandlingen af epilepsi
CA2739416C (en) * 2008-09-03 2017-10-31 Arbor Vita Corporation Agents and methods for treatment of pain

Also Published As

Publication number Publication date
WO2009140416A2 (en) 2009-11-19
CA2724483A1 (en) 2009-11-19
EP2307035B1 (en) 2013-12-04
EP2307035A2 (en) 2011-04-13
CN102088990A (zh) 2011-06-08
US9161965B2 (en) 2015-10-20
US20100160240A1 (en) 2010-06-24
ES2446306T3 (es) 2014-03-07
AU2009246316A1 (en) 2009-11-19
JP2016199553A (ja) 2016-12-01
JP2011520900A (ja) 2011-07-21
JP6005357B2 (ja) 2016-10-12
AU2009246316B2 (en) 2014-06-19
EP2307035A4 (en) 2012-04-11
WO2009140416A3 (en) 2010-01-14
DK2307035T3 (da) 2014-01-20

Similar Documents

Publication Publication Date Title
CA2724483C (en) Psd-95 inhibitor for the treatment of epilepsy
AU2008272903B2 (en) Treatment for anxiety
ES2446292T3 (es) Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N
ES2847293T3 (es) Regímenes de tratamiento para el tratamiento de enfermedades neurológicas
ES2804424T3 (es) Péptido y composición del mismo para usar en el tratamiento del accidente cerebrovascular con fiebre
EP2616094B1 (en) Treatment of penetrative injury to the brain
AU2008335490A1 (en) Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
CN109718363B (zh) 预防、缓解或治疗阿尔茨海默病的肽及其应用
RU2607033C2 (ru) Пептиды nd2 и способы лечения неврологического заболевания
KR20180135492A (ko) 흥분성 신경독성 관련 손상 치료용 펩타이드
Chambel Urinary dysfunction after spinal cord injury: resolving neuronal mechanisms behind neurogenic detrusor overactivity
de Sousa Chambel Urinary Dysfunction After Spinal Cord Injury Resolving Neuronal Mechanisms Behind Neurogenic Detrusor Overactivity
Donev Ion Channels as Therapeutic Targets, Part B
KR20180135493A (ko) 흥분성 신경독성 관련 손상의 치료 방법

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140407

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251110

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20251113

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260224